Results 181 to 190 of about 244,635 (318)

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Blood, 2017
M. Crump, S. Neelapu, U. Farooq, E. Van Den Neste, J. Kuruvilla, J. Westin, B. Link, A. Hay, J. Cerhan, Liting Zhu, S. Boussetta, Lei Feng, M. Maurer, L. Navale, J. Wiezorek, W. Go, C. Gisselbrecht   +16 more
semanticscholar   +1 more source

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.

Cancer Cell, 2021
C. Steen, Bogdan Luca, M. S. Esfahani, Armon Azizi, B. Sworder, B. Nabet, D. Kurtz, C. Liu, Farnaz Khameneh, R. Advani, Y. Natkunam, J. Myklebust, M. Diehn, A. Gentles, Aaron M. Newman, A. Alizadeh   +15 more
semanticscholar   +1 more source

Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides

The Journal of Dermatology, EarlyView.
ABSTRACT Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T‐cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin‐fixed, paraffin‐embedded (FFPE) tissue for GATA3 (n = 20), T‐bet (n = 22)
Bruno de Castro e Souza, Denis Miyashiro, Jade Cury‐Martins, Neusa Yuriko Sakai Valente, Luiz Fernando Ferraz da Silva, José Antonio Sanches   +5 more
wiley   +1 more source

Laparoscopic Splenectomy for Inflammatory Pseudotumor‐Like Follicular Dendritic Cell Sarcoma: A RareEpstein–Barr Virus‐Associated Splenic Tumor

The Kaohsiung Journal of Medical Sciences, EarlyView.
Hsin‐Yi Lin, Po‐Hsuan Wu, Hui‐Gin Chiu, Jia‐Yu Chen   +3 more
wiley   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

A high‐throughput bone marrow 3D co‐culture system to study resistance to BCR signalling targeted agents in B‐NHL

British Journal of Haematology, EarlyView.
Bone marrow (BM) involvement in B‐cell non‐Hodgkin lymphoma (B‐NHL) is associated with poor prognosis, as the BM microenvironment provides a protective niche that promotes therapeutic resistance. We developed a simplified, automated and high‐throughput 3D BM co‐culture model that faithfully reproduces key tumour–stroma interactions.
Alex Zadro, Alberto Arribas, Maria Vittoria Colombo, Eleonora Cannas, Filippo Spriano, Luciano Cascione, Afua Adjeiwaa Mensah, Federico Simonetta, Dalila Petta, Christian Candrian, Chiara Arrigoni, Francesco Bertoni, Matteo Moretti   +12 more
wiley   +1 more source

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

British Journal of Haematology, EarlyView.
Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong, Johanna Bult, Nick Veltmaat, Filipe Montes de Jesus, Laurens Sillje, Joost Kluiver, Anke van den Berg, Wouter Plattel, Arjan Diepstra, Marcel Nijland   +9 more
wiley   +1 more source

Rarity to Remission: Complete Response of Primary Breast Diffuse Large B-Cell Lymphoma With Chemoimmunotherapy. [PDF]

Clin Case Rep
Jha A, Ghosh V, Gupta S, Oli S, Rayamajhi A, Gupta D, Luitel A, Khanal B, Dahal A, Khadka S.   +9 more
europepmc   +1 more source

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine, 2015
W. Wilson, R. Young, R. Schmitz, Yandan Yang, S. Pittaluga, George W. Wright, C. Lih, P. Williams, A. Shaffer, J. Gerecitano, J. Gerecitano, S. Vos, A. Goy, V. Kenkre, P. Barr, K. Blum, A. Shustov, R. Advani, N. Fowler, J. Vose, R. Elstrom, T. Habermann, J. Barrientos, J. Mcgreivy, M. Fardis, B. Chang, F. Clow, B. Munneke, D. Moussa, D. Beaupre, L. Staudt   +30 more
semanticscholar   +1 more source

Clinical features and incidence of central nervous system involvement in patients with adult T‐cell leukaemia/lymphoma

British Journal of Haematology, EarlyView.
Summary Central nervous system (CNS) involvement is a known complication of adult T‐cell leukaemia/lymphoma (ATL), but its clinical characteristics and incidence still remain unclear. This study characterized the clinical features and incidence of CNS involvement in patients with ATL (CNS‐ATL).
Takuya Ueno, Makoto Yoshimitsu, Momone Sameshima, Taichi Nagano, Rika Akahoshi, Yusetsu Takeshita, Aya Shodai, Kodai Shima, Naosuke Arima, Yuhei Kamada, Daisuke Nakamura, Kenji Ishitsuka   +11 more
wiley   +1 more source